Promise of Eli Lilly’s weight-loss drug for sleep apnea adds one other purpose to bear the inventory

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan Mcdermid | Reuters

Eli Lilly‘s weight-loss drug Zepbound confirmed promise as a treatment for sleep apnea — giving traders more self belief to preserve proudly owning the sphere’s most treasured smartly being-care firm even after it is been crushing the S&P 500’s efficiency over the past three years.

Content Protection by DMCA.com

Back to top button